This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.
Dr. Long will be responsible for clinical studies performed in China. His extensive experience and knowledge in preclinical and clinical regulations will strengthen Sirnaomics clinical programs for novel siRNA therapeutic development in China.
Sirnaomics announced today that the Office of Orphan Product Development division of the FDA has granted Orphan-drug designation to its leading therapeutic candidate, STP705, for the treatment of Cholangiocarcinoma (CCA).
The manuscript is titled “Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis” (Oncotarget, September, 2017).
Sirnaomics announced today that the Office of Orphan Product Development division of the USA FDA has granted Orphan Drug Designation to its leading therapeutic candidate, STP705, for the treatment of Primary Sclerosing Cholangitis (PSC).
Sirnaomics announced today that it has received reports from efficacy studies with CCL4-Induced mouse liver fibrosis model for its lead siRNA therapeutic candidate, STP705 (Cotsiranib®), from two contract research companies.